Polyphor launches the development of an inhaled antibiotic murepavadin
Polyphor Ltd has announced the development of an inhaled dosage form of its breakthrough antibiotic Murepavadin. Continue reading New Inhaled Antibiotic To Treat Respiratory Infections
IUPUI microbiologists uncover clues to clustering of lethal bacteria in CF patients’ lungs
Individuals with cystic fibrosis, or CF, have a high risk of chronic pneumonia because the thick, sticky mucus that builds up in Continue reading Microbiologists uncover clues to clustering of lethal bacteria in CF patients’ lungs
Canadian scientists have discovered a possible way to break through the defences of some antibiotic-resistant respiratory infections.
It’s hoped that the findings could someday benefit people with cystic fibrosis and other chronic lung diseases who are at greater risk of infections. Continue reading Scientists find new way to attack antibiotic-resistant lung infections
New Drug Application Submitted for Linhaliq as Treatment of Pseudomonas Aeruginosa Infection in NCFBE Patients
The pharmaceutical company Aradigm has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Linhaliq Continue reading New Drug Application Submitted for Treatment of P. aeruginosa
CARB-X has awarded $8.9M (€7.6M) to Antabio for the development of a new antibiotic against resistant Pseudomonas infections in cystic fibrosis patients.
Antabio is a French company developing new antibiotics to fight the rapidly Continue reading French Biotech Receives an Award to Develop a Novel Cystic Fibrosis Antibiotic
I’m not naïve enough to think that I’m going to wake up tomorrow and find that my life is moving forward with cystic fibrosis in the rearview mirror.
We’re still a little bit away from that moment, but that doesn’t mean I don’t have high expectations for treatment development. Continue reading My Wish List for the New Year By Gunnar Esiason
An investigation led by the University of Pittsburgh School of Medicine has found a link between a new class of bacterial enzymes and the chronic lung inflammation that plagues patients with cystic fibrosis, a terminal lung Continue reading Pitt study links cystic fibrosis lung inflammation to opportunistic bacteria